Spire Healthcare Group - SPI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 302.25
  • Forecasted Upside: 24.13%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
GBX 243.50
▼ -0.5 (-0.20%)

This chart shows the closing price for SPI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spire Healthcare Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPI

Analyst Price Target is GBX 302.25
▲ +24.13% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Spire Healthcare Group in the last 3 months. The average price target is GBX 302.25, with a high forecast of GBX 344 and a low forecast of GBX 260. The average price target represents a 24.13% upside from the last price of GBX 243.50.

This chart shows the closing price for SPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Spire Healthcare Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/18/2024JPMorgan Chase & Co.Reiterated RatingOverweightGBX 344
4/17/2024Berenberg BankBoost TargetBuyGBX 286 ➝ GBX 300
2/29/2024Berenberg BankReiterated RatingBuyGBX 286
2/26/2024JPMorgan Chase & Co.Reiterated RatingOverweightGBX 295
11/13/2023Royal Bank of CanadaLower TargetOutperformGBX 270 ➝ GBX 260
9/18/2023Berenberg BankReiterated RatingBuyGBX 286
9/15/2023JPMorgan Chase & Co.Boost TargetOverweightGBX 249 ➝ GBX 280
9/15/2023BarclaysBoost TargetOverweightGBX 300 ➝ GBX 305
9/9/2022JPMorgan Chase & Co.Lower TargetOverweightGBX 347 ➝ GBX 341
9/9/2022Shore CapitalReiterated RatingHouse Stock
9/8/2022Berenberg BankReiterated RatingBuyGBX 300
8/17/2022BarclaysLower TargetOverweightGBX 310 ➝ GBX 305
7/19/2022Royal Bank of CanadaBoost TargetSector PerformGBX 240 ➝ GBX 260
7/12/2022Berenberg BankReiterated RatingBuyGBX 300
6/30/2022JPMorgan Chase & Co.Lower TargetOverweightGBX 347 ➝ GBX 237
6/30/2022Berenberg BankReiterated RatingBuyGBX 300
6/21/2022Berenberg BankReiterated RatingHoldGBX 300
5/31/2022BarclaysReiterated RatingOverweightGBX 310
4/5/2022BarclaysReiterated RatingOverweightGBX 310
3/24/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 240
3/11/2022BarclaysBoost TargetOverweightGBX 300 ➝ GBX 310
3/10/2022JPMorgan Chase & Co.Boost TargetOverweightGBX 296 ➝ GBX 347
2/4/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 240
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
12/14/2021BarclaysReiterated RatingOverweightGBX 300
12/3/2021BarclaysReiterated RatingOverweightGBX 300
10/21/2021BarclaysReiterated RatingOverweightGBX 280
9/10/2021BarclaysUpgradeOverweightGBX 165 ➝ GBX 280
5/27/2021Liberum CapitalReiterated RatingHoldGBX 180
5/26/2021Peel HuntReiterated RatingBuyGBX 233
5/26/2021Peel HuntReiterated RatingBuyGBX 233
5/13/2021Numis SecuritiesReiterated RatingAddGBX 180
4/8/2021Royal Bank of CanadaBoost TargetOutperformGBX 169 ➝ GBX 200
2/9/2021Liberum CapitalDowngradeHoldGBX 180
9/28/2020JPMorgan Chase & Co.UpgradeOverweightGBX 136 ➝ GBX 175
7/27/2020UBS GroupLower TargetNeutralGBX 121 ➝ GBX 97
7/22/2020BarclaysReiterated RatingUnderweight
7/10/2020Morgan StanleyDowngradeEqual weightGBX 156 ➝ GBX 99
7/8/2020Jefferies Financial GroupReiterated RatingUnderperformGBX 113 ➝ GBX 67
7/2/2020Liberum CapitalReiterated RatingHold
7/1/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/14/2020Peel HuntReiterated RatingBuy
5/11/2020Royal Bank of CanadaDowngradeSector PerformerGBX 100
5/1/2020Peel HuntReiterated RatingBuy
4/24/2020Peel HuntReiterated RatingBuy
4/14/2020Peel HuntReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
4/7/2020Liberum CapitalReiterated RatingHold
4/1/2020Peel HuntReiterated RatingBuy
4/1/2020Liberum CapitalReiterated RatingHold
3/24/2020Royal Bank of CanadaReiterated RatingOutperform
3/19/2020Peel HuntUpgradeBuy
3/18/2020Royal Bank of CanadaLower TargetOutperformGBX 149 ➝ GBX 100
3/18/2020Liberum CapitalReiterated RatingHold
3/13/2020Peel HuntReiterated RatingAdd
3/10/2020Liberum CapitalLower TargetHoldGBX 133 ➝ GBX 125
3/5/2020Peel HuntReiterated RatingAdd
2/11/2020UBS GroupBoost TargetNeutralGBX 117 ➝ GBX 121
2/5/2020Peel HuntReiterated RatingAdd
1/27/2020Liberum CapitalReiterated RatingHold
1/27/2020Peel HuntReiterated RatingAdd
1/21/2020Jefferies Financial GroupDowngradeUnderperformGBX 106 ➝ GBX 113
1/16/2020Peel HuntReiterated RatingAdd
1/13/2020Liberum CapitalBoost TargetHoldGBX 125 ➝ GBX 133
1/8/2020Peel HuntReiterated RatingAddGBX 155
1/7/2020BarclaysReiterated RatingUnderweight
1/7/2020Peel HuntReiterated RatingAddGBX 155
12/13/2019Peel HuntReiterated RatingAdd
12/5/2019Peel HuntReiterated RatingAdd
11/15/2019Jefferies Financial GroupReiterated RatingHold
11/12/2019Liberum CapitalBoost TargetHoldGBX 115 ➝ GBX 120
11/1/2019Peel HuntReiterated RatingAdd
9/16/2019Peel HuntReiterated RatingAddGBX 155
9/16/2019UBS GroupReiterated RatingNeutralGBX 120
9/16/2019Peel HuntUpgradeAddGBX 155
9/9/2019Royal Bank of CanadaReiterated RatingOutperformGBX 149
9/2/2019Peel HuntReiterated RatingHold
8/9/2019BarclaysReiterated RatingUnderweightGBX 115
8/5/2019Liberum CapitalReiterated RatingHold
8/1/2019Peel HuntReiterated RatingHold
7/11/2019Peel HuntReiterated RatingHold
7/11/2019Liberum CapitalReiterated RatingHold
7/3/2019Peel HuntReiterated RatingHold
7/2/2019UBS GroupInitiated CoverageNeutralGBX 120
(Data available from 6/13/2019 forward)

News Sentiment Rating

-0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
2/14/2024
  • 4 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/14/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/14/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Spire Healthcare Group logo
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory medicine, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology, vascular surgery, weight loss, and women's health. Further, the company offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. It offers in-patient, daycase, and out-patient care services through hospitals and clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 243.50
Low: 242.50
High: 249.50

50 Day Range

MA: GBX 250.37
Low: 231.50
High: 321.71

52 Week Range

Now: GBX 243.50
Low: 204
High: 270.50

Volume

350,842 shs

Average Volume

496,317 shs

Market Capitalization

£983.30 million

P/E Ratio

3,478.57

Dividend Yield

1.02%

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Spire Healthcare Group?

The following equities research analysts have issued research reports on Spire Healthcare Group in the last twelve months: Barclays PLC, Berenberg Bank, JPMorgan Chase & Co., and Royal Bank of Canada.
View the latest analyst ratings for SPI.

What is the current price target for Spire Healthcare Group?

4 Wall Street analysts have set twelve-month price targets for Spire Healthcare Group in the last year. Their average twelve-month price target is GBX 302.25, suggesting a possible upside of 24.1%. JPMorgan Chase & Co. has the highest price target set, predicting SPI will reach GBX 344 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of GBX 260 for Spire Healthcare Group in the next year.
View the latest price targets for SPI.

What is the current consensus analyst rating for Spire Healthcare Group?

Spire Healthcare Group currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPI will outperform the market and that investors should add to their positions of Spire Healthcare Group.
View the latest ratings for SPI.

What other companies compete with Spire Healthcare Group?

How do I contact Spire Healthcare Group's investor relations team?

Spire Healthcare Group's physical mailing address is 3 Dorset Rise, LONDON, EC4Y 8EN, United Kingdom. The company's listed phone number is 44 20 7427 9000. The official website for Spire Healthcare Group is investors.spirehealthcare.com. Learn More about contacing Spire Healthcare Group investor relations.